Comparative Pharmacology
Head-to-head clinical analysis: ILOSONE SULFA versus TRYSUL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOSONE SULFA versus TRYSUL.
ILOSONE SULFA vs TRYSUL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ilosone (erythromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Sulfa (sulfisoxazole) is a sulfonamide that inhibits dihydropteroate synthase, blocking folate synthesis. The combination provides synergistic bacteriostatic activity.
Trypanocidal agent; forms a complex with DNA and inhibits nucleic acid synthesis.
Each 5 mL suspension contains 250 mg erythromycin base and 600 mg sulfisoxazole; typical adult dose is 10 mL (2 tsp) every 6 hours, not to exceed 40 mL/day.
2 tablets (each containing sulfamethoxazole 400 mg and trimethoprim 80 mg) orally every 12 hours for 10-14 days.
None Documented
None Documented
Erythromycin: 1.5-2 hours; Sulfisoxazole: 4-7 hours; clinical context: dose adjustment in renal impairment (CrCl <50 mL/min) needed for sulfisoxazole
Terminal elimination half-life: 8-10 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70-80% as unchanged drug and active metabolite (sulfisoxazole); Biliary: 10-15% as metabolites; Fecal: <5%
Renal: approximately 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: 15-20% as metabolites; small amount in feces.
Category C
Category C
Macrolide and Sulfonamide Antibiotic
Sulfonamide Antibiotic